The proadhesive phenotype of systemic sclerosis skin promotes myeloid cell adhesion via ICAM-1 and VCAM-1

Rheumatology

Volumn 48, Issue 7, 2009, Pages 734-740

  Rabquer, Bradley J ^a,e   Hou, Yong ^a   Del Galdo, Francesco ^b   Kenneth III, Haines G ^c   Gerber, Michele L ^a   Jimenez, Sergio A ^b   Seibold, James R ^a   Koch, Alisa E ^a,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e NONE   (United States)

Author keywords

Adhesion molecules; ICAM 1; Junctional adhesion molecules; Systemic sclerosis; VCAM 1

Indexed keywords

CD99 ANTIGEN; JUNCTIONAL ADHESION MOLECULE B; JUNCTIONAL ADHESION MOLECULE C; MEMBRANE PROTEIN; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; BONE MARROW CELL; CELL ADHESION; CELL INFILTRATION; CELL STRAIN U937; CELL SURFACE; CELL TYPE; CONTROLLED STUDY; ENDOTHELIUM CELL; EPIDERMIS; FIBROBLAST; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LEUKOCYTE ADHERENCE; MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; SKIN; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS;

ANIMALS; ANTIGENS, CD; CASE-CONTROL STUDIES; CELL ADHESION; CELL ADHESION MOLECULES; COCULTURE TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR ADHESION MOLECULE-1; MICE; MYELOID CELLS; SCLERODERMA, SYSTEMIC; SKIN; U937 CELLS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 67650083220     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep091     Document Type: Article

References (35)

1. Maricq HR, Spencer-Green G, LeRoy EC. Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis. Am J Med 1976;61:862-70.
2. Maricq HR. Wide-field capillary microscopy. Arthritis Rheum 1981;24:1159-65.
3. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin1 in patients with systemic sclerosis: Relationship to organ systemic involvement. Clin Rheumatol 2005;24:111-16.
4. Denton CP, Bickerstaff MC, Shiwen X et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 1995;34:1048-54.
5. Ihn H, Sato S, Fujimoto M et al. Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines. Br J Rheumatol 1997;36:1270-5.
6. Sfikakis PP, Tesar J, Baraf H, Lipnick R, Klipple G, Tsokos GC. Circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Immunol Immunopathol 1993;68:88-92.
7. Allanore Y, Borderie D, Lemarechal H, Ekindjian OG, Kahan A. Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1. Arthritis Res Ther 2004;6:R309-14.
8. Apras S, Ertenli I, Ozbalkan Z et al. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 2003;48:2256-61.
9. Cho M, Jimenez SA, Johnson B, Harlow LA, Burrows JC, Koch AE. Cytokine regulation of intercellular adhesion molecule-1 expression in scleroderma fibroblasts. Pathobiology 1994;62:73-81.
10. Iannone F, Matucci-Cerinic M, Falappone PC et al. Distinct expression of adhesion molecules on skin fibroblasts from patients with diffuse and limited systemic sclerosis. A pilot study. J Rheumatol 2005;32:1893-8.
11. Koch AE, Kronfeld-Harrington LB, Szekanecz Z et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology 1993;61:239-46.
12. Sollberg S, Peltonen J, Uitto J, Jimenez SA. Elevated expression of beta 1 and beta 2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. Arthritis Rheum 1992;35:290-98.
13. Abraham D, Lupoli S, McWhirter A et al. Expression and function of surface antigens on scleroderma fibroblasts. Arthritis Rheum 1991;34:1164-72.
14. Rudnicka L, Majewski S, Blaszczyk M et al. Adhesion of peripheral blood mononuclear cells to vascular endothelium in patients with systemic sclerosis (scleroderma). Arthritis Rheum 1992;35:771-5.
15. Sato S. Abnormalities of adhesion molecules and chemokines in scleroderma. Curr Opin Rheumatol 1999;11:503-7.
16. Schenkel AR, Mamdouh Z, Chen X, Liebman RM, Muller WA. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol 2002;3:143-50.
17. Weber C, Fraemohs L, Dejana E. The role of junctional adhesion molecules in vascular inflammation. Nat Rev Immunol 2007;7:467-77.
18. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
19. Louneva N, Huaman G, Fertala J, Jimenez SA. Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum 2006;54:1298-308.
20. Aurrand-Lions M, Duncan L, Ballestrem C, Imhof BA. JAM-2, a novel immunoglobulin superfamily molecule, expressed by endothelial and lymphatic cells. J Biol Chem 2001;276:2733-41.
21. Amin MA, Haas CS, Zhu K et al. Migration inhibitory factor up-regulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 via Src, PI3 kinase, and NFkappaB. Blood 2006;107:2252-61.
22. Lamagna C, Meda P, Mandicourt G et al. Dual interaction of JAM-C with JAM-B and alpha(M)beta2 integrin: Function in junctional complexes and leukocyte adhesion. Mol Biol Cell 2005;16:4992-5003.
23. Claman HN, Giorno RC, Seibold JR. Endothelial and fibroblastic activation in scleroderma. The myth of the "uninvolved skin". Arthritis Rheum 1991;34: 1495-501.
24. Mandell KJ, Parkos CA. The JAM family of proteins. Adv Drug Deliv Rev 2005;57:857-67.
25. Liang TW, Chiu HH, Gurney A et al. Vascular endothelial-junctional adhesion molecule (VE-JAM)/JAM 2 interacts with T, NK, and dendritic cells through JAM 3. J Immunol 2002;168:1618-26.
26. Lamagna C, Hodivala-Dilke KM, Imhof BA, Aurrand-Lions M. Antibody against junctional adhesion molecule-C inhibits angiogenesis and tumor growth. Cancer Res 2005;65:5703-10.
27. Petri B, Bixel MG. Molecular events during leukocyte diapedesis. FEBS J 2006;273:4399-407.
28. Bixel G, Kloep S, Butz S, Petri B, Engelhardt B, Vestweber D. Mouse CD99 participates in T-cell recruitment into inflamed skin. Blood 2004;104:3205-13.
29. Marlor CW, Webb DL, Bombara MP, Greve JM, Blue ML. Expression of vascular cell adhesion molecule-1 in fibroblastlike synoviocytes after stimulation with tumor necrosis factor. Am J Pathol 1992;140:1055-60.
30. Scala E, Pallotta S, Frezzolini A et al. Cytokine and chemokine levels in systemic sclerosis: Relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004;138:540-6.
31. Kurasawa K, Hirose K, Sano H et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000;43:2455-63.
32. Yao Z, Painter SL, Fanslow WC et al. Human IL-17: A novel cytokine derived from T cells. J Immunol 1995;155:5483-6.
33. Cunningham SA, Rodriguez JM, Arrate MP, Tran TM, Brock TA. JAM2 interacts with alpha4beta1. Facilitation by JAM3. J Biol Chem 2002;277:27589-92.
34. Santoso S, Sachs UJ, Kroll H et al. The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med 2002;196:679-91.
35. Lou O, Alcaide P, Luscinskas FW, Muller WA. CD99 is a key mediator of the transendothelial migration of neutrophils. J Immunol 2007;178:1136-43.